Intellia Therapeutics, Inc.(NTLA)Earnings, Financials & Key Ratios

CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

It might pull it off, provided several things fall right in place.

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.

Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FDA approval of Yartemlea and a significant development deal with Novo Nordisk.

Stocks are mixed, with the Dow Jones Industrial Average (DJI) trading at fresh record highs once again